Effects of the 11 beta-hydroxysteroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in men with type 2 diabetes.
about
11Beta-hydroxysteroid dehydrogenase inhibition improves cognitive function in healthy elderly men and type 2 diabeticsEmodin, a natural product, selectively inhibits 11beta-hydroxysteroid dehydrogenase type 1 and ameliorates metabolic disorder in diet-induced obese miceThe role of glucocorticoid action in the pathophysiology of the Metabolic SyndromeIdiopathic intracranial hypertension, hormones, and 11β-hydroxysteroid dehydrogenasesChem2Bio2RDF: a semantic framework for linking and data mining chemogenomic and systems chemical biology data11beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of type 2 diabetes.Pathogenesis of non-alcoholic fatty liver disease.Effect of 11 beta-hydroxysteroid dehydrogenase-1 inhibition on hepatic glucose metabolism in the conscious dog.Current therapies and emerging drugs in the pipeline for type 2 diabetes.Ketoconazole enantiomer for the treatment of diabetes mellitus.Synthesis, biology and clinical significance of pentacyclic triterpenes: a multi-target approach to prevention and treatment of metabolic and vascular diseases.Reduction of hepatic glucocorticoid receptor and hexose-6-phosphate dehydrogenase expression ameliorates diet-induced obesity and insulin resistance in mice.11β-Hydroxysteroid dehydrogenase type 1: relevance of its modulation in the pathophysiology of obesity, the metabolic syndrome and type 2 diabetes mellitus.Carbenoxolone treatment ameliorated metabolic syndrome in WNIN/Ob obese rats, but induced severe fat loss and glucose intolerance in lean rats.Increased whole-body and sustained liver cortisol regeneration by 11beta-hydroxysteroid dehydrogenase type 1 in obese men with type 2 diabetes provides a target for enzyme inhibitionGlucocorticoids regulate the metabolic hormone FGF21 in a feed-forward loop.11β-hydroxysteroid dehydrogenases and the brain: from zero to hero, a decade of progress.Discovery of adamantyl heterocyclic ketones as potent 11β-hydroxysteroid dehydrogenase type 1 inhibitorsAdamantyl ethanone pyridyl derivatives: potent and selective inhibitors of human 11β-hydroxysteroid dehydrogenase type 111beta-hydroxysteroid dehydrogenase type 1 as a novel therapeutic target in metabolic and neurodegenerative disease.Ubiquitin-specific protease 2 regulates hepatic gluconeogenesis and diurnal glucose metabolism through 11β-hydroxysteroid dehydrogenase 1Novel Agents for the Treatment of Type 2 Diabetes.The role of cortisol in the pathogenesis of the metabolic syndromeTissue-specific dysregulation of 11beta-hydroxysteroid dehydrogenase type 1 and pathogenesis of the metabolic syndrome.Inhibition of 11beta-HSD1 as a novel treatment for the metabolic syndrome: do glucocorticoids play a role?The Hypothalamic-Pituitary-Adrenal Axis, Obesity, and Chronic Stress Exposure: Sleep and the HPA Axis in ObesityMechanisms of disease: Selective inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a novel treatment for the metabolic syndrome.Glucocorticoids produce whole body insulin resistance with changes in cardiac metabolism.Tissue production of cortisol by 11beta-hydroxysteroid dehydrogenase type 1 and metabolic disease.Peroxisome Proliferators-Activated Receptor (PPAR) Modulators and Metabolic Disorders.Stress and Its Effects on Glucose Metabolism and 11β-HSD Activities in Rats Fed on a Combination of High-Fat and High-Sucrose Diet with Glycyrrhizic Acid.11β-hydroxysteroid dehydrogenase inhibition as a new potential therapeutic target for alcohol abuseInvestigating the role of cortisol and growth hormone in fatty liver development: fatty liver index in patients with pituitary adenomas.A novel NADP(+)-dependent dehydrogenase activity for 7alpha/beta- and 11beta-hydroxysteroids in human liver nuclei: A third 11beta-hydroxysteroid dehydrogenase.11beta-hydroxysteroid dehydrogenase type 1 inhibitors: a review of recent patents.Mechanisms of glucocorticoid-induced insulin resistance: focus on adipose tissue function and lipid metabolism.Elevated hepatic 11β-hydroxysteroid dehydrogenase type 1 induces insulin resistance in uremia.11β-hydroxysteroid dehydrogenases: intracellular gate-keepers of tissue glucocorticoid action.Diabetes area participation analysis: a review of companies and targets described in the 2008 - 2010 patent literature.The glucocorticoid contribution to obesity.
P2860
Q24564713-C402633B-B301-4780-843F-3062CCD253EDQ24627436-FBBD1065-1440-47A7-B1A7-7A7E904A0A58Q24803696-3599C1FE-F18C-4C14-8CB7-4D5EA0D86711Q26749288-5E25ACE4-846A-407A-941B-BFD2BFD34771Q27136634-0B76DBDE-AA84-4289-B881-82331F514013Q30392597-EB7EB0B5-2CD8-413C-91EF-EC3926A4BD5DQ33606303-90FBDDE7-F392-4E4D-A32C-4409D1436249Q33840328-D661F50F-35C4-4AA5-80E6-00CB32A5231AQ33928941-8A3A6597-3BAA-45AD-8046-805CD415990DQ34090860-C2213C52-45A7-4597-AE28-7E7F305EE141Q34162283-5A6FE0CC-D5DB-4296-8F03-05978EF6F3ABQ34197575-EEBCB418-992E-4EF7-89AA-4C9654EBDF87Q34253331-056F59CB-61E9-4188-939A-E9682909EDE8Q34531519-9562F979-95D6-4FF1-BAA7-92D8D32432C5Q34615362-CE53D279-710A-41BE-ADE5-747DDE3D3F8CQ35054990-708BB539-7FFA-4FA8-AED1-89A7E936BACDQ35144168-86BF3C66-55B2-47C4-97DF-A527D99B41B1Q35207855-8520C7DD-9140-43F2-8335-56263311DEE8Q35231710-9D12CD3F-AD19-44E2-BEDC-5F68F230E946Q35593949-0C66DC6D-CCDE-47EE-9333-D02E72F78E93Q35902915-3BFD168B-1FF9-4498-9C52-01C5C5442B5AQ35910421-318AFFE8-3E04-45C4-A375-FFE36B79B161Q36049207-E3C6D30E-F455-4601-A77F-5AB41253C8ACQ36068444-372146CB-40E4-4500-9F92-E8ABE93DB289Q36266034-38046EA5-1FEB-4D21-AD20-AD52043C4946Q36399676-181EC31E-ED2A-4ECC-A021-B6D5B840DBE8Q36575445-B48B2D38-CFD5-4FAD-A13A-2E32D18D2EC9Q36640675-E9FF02C7-682F-4A2B-8D8A-D7D7990A776DQ36674845-58581BB9-6F5C-4517-9B71-B8B45B6F0DB6Q36724770-D2CA58D2-1B96-4F50-8019-AD55ED34A6F6Q36825800-950C5EFA-418C-4C61-99B4-16A4CB9621F0Q36915489-91582717-75BB-4B6E-986C-C768EFF8751AQ37201576-E2283EFA-E29B-405F-8385-01AD98EB637AQ37344150-5E38EDE4-6F05-4376-8028-87A4DC30CB7BQ37489938-0902BD41-5A61-474E-A037-64E02140D1E9Q37617588-A31C2635-5896-4797-9AE7-FCC10F31D534Q37640920-2BB6816E-06BE-458C-A00A-216B85956F4BQ37655884-10E95910-C939-4DB2-9FF2-8DF0A7D4211CQ37810292-9C4B22E9-1CD4-4F57-9689-39CCD07E2970Q37835838-3184AD20-A7DF-465E-AA9B-753BD1A1768E
P2860
Effects of the 11 beta-hydroxysteroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in men with type 2 diabetes.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Effects of the 11 beta-hydroxy ...... y in men with type 2 diabetes.
@en
Effects of the 11 beta-hydroxy ...... y in men with type 2 diabetes.
@nl
type
label
Effects of the 11 beta-hydroxy ...... y in men with type 2 diabetes.
@en
Effects of the 11 beta-hydroxy ...... y in men with type 2 diabetes.
@nl
prefLabel
Effects of the 11 beta-hydroxy ...... y in men with type 2 diabetes.
@en
Effects of the 11 beta-hydroxy ...... y in men with type 2 diabetes.
@nl
P356
P1476
Effects of the 11 beta-hydroxy ...... ty in men with type 2 diabetes
@en
P2093
Brian R Walker
Olav Rooyackers
P304
P356
10.1210/JC.2002-021194
P407
P577
2003-01-01T00:00:00Z